Vandefitemcel Stem Cell Therapy for Chronic Cortical Hyperexcitability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for chronic cortical hyperexcitability following ischemic stroke, which leads to motor disorders, chronic pain, and epilepsy, and there is a need for therapies that can improve neural plasticity and reduce pathological cortical hyperexcitability.
Innovation Solution
Administering vandefitemcel, a type of human bone marrow-derived mesenchymal stem cells transiently-transfected with a polynucleotide encoding a Notch intracellular domain (NICD), to increase production of GABA transporters, brain-derived neurotrophic factors, and other neuroprotective agents in specific brain regions to treat chronic cortical hyperexcitability and reverse stroke-induced changes in gene and protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional stroke treatments (thrombolytic therapy, neurorehabilitation training) are used, then acute stroke management is improved, but chronic corticalhyperexcitability and neurological disabilities persist
Solution Approach 1:
The patent converts the harmful effect of stroke-induced corticalhyperexcitability into a beneficial outcome by using MSC-based therapy to restore normal cortical excitability. The therapy targets the pathological plasticity caused by stroke and transforms it into improved neural function, thereby converting the harmful chronic hyperexcitability into a benefit through targeted cellular intervention.
Solution Approach 2:
The patent applies parameter changes by modifying the expression levels of specific genes (e.g., GAT1, BDNF) and proteins in the brain tissue. The MSC-based therapy alters the biochemical parameters of the stroke-affected cortex, restoring normal excitability by changing the expression of neurotransmitter transporters and neurotrophic factors, thereby resolving the chronic hyperexcitability issue.
2Adaptability or versatility
If mesenchymal stem cell-based therapy is used, then neural plasticity is improved, but the treatment complexity increases
Solution Approach 1:
The patent applies self-service by utilizing the inherent properties of mesenchymal stem cells to promote neural plasticity and repair. The MSCs autonomously differentiate into relevant cell types, secrete neurotrophic factors, and integrate into the host tissue without requiring external guidance or complex intervention mechanisms. This self-organizing capability simplifies the treatment approach while maintaining high neural plasticity.
Solution Approach 2:
The patent demonstrates multi-functionality by showing that MSC-based therapy can simultaneously improve neural plasticity, reduce corticalhyperexcitability, and promote functional recovery. The same cell type performs multiple therapeutic functions, including neuroprotection, synaptogenesis, and modulation of excitability, thereby achieving versatile outcomes without proportionally increasing treatment complexity.
3Reliability
If chronic corticalhyperexcitability is treated, then neurological disabilities are reduced, but the timing of intervention becomes critical
Solution Approach 1:
The patent applies preliminary action by initiating MSC-based therapy at optimal time points following stroke to prevent the establishment of chronic hyperexcitability. By timing the intervention to occur before maladaptive plasticity fully consolidates, the therapy can more effectively prevent neurological disabilities rather than merely treating established chronic conditions, thereby reducing the time loss associated with delayed intervention.
Data Source
AI summary
Disclosed are compositions and methods for treating cortical hyperexcitability and reversing stroke-induced changes in gene expression and protein expression. For example, the methods can comprise administering vandefitemcel to a region of the brain of a subject to reduce chronic cortical hyperexcitability in the subject. Also disclosed are methods and blood biomarker panels for assessing an efficacy of a stem cell treatment for a chronic condition caused by stroke.